Literature DB >> 21764132

Synergistic targeting of leukemia with leukotoxin and chemotherapy.

Robert J Kreitman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21764132      PMCID： PMC7458126          DOI： 10.1016/j.leukres.2011.06.028

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  7 in total

1.  In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.

Authors:  Anukriti Gupta; Amy Le; Benjamin A Belinka; Scott C Kachlany
Journal:  Leuk Res       Date:  2011-06-12       Impact factor: 3.156

2.  Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells.

Authors:  C N Kim; K Bhalla; R J Kreitman; M C Willingham; P Hall; E P Tagge; T Jia; A E Frankel
Journal:  Leuk Res       Date:  1999-06       Impact factor: 3.156

3.  Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Authors:  Raffit Hassan; Susie Bullock; Ahalya Premkumar; Robert J Kreitman; Hedy Kindler; Mark C Willingham; Ira Pastan
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

4.  Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.

Authors:  Yujian Zhang; Laiman Xiang; Raffit Hassan; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-16       Impact factor: 11.205

5.  Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

Authors:  Robert J Kreitman; Raffit Hassan; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

6.  Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF.

Authors:  A E Frankel; P D Hall; C McLain; A R Safa; E P Tagge; R J Kreitman
Journal:  Bioconjug Chem       Date:  1998 Jul-Aug       Impact factor: 4.774

7.  Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.

Authors:  Raffit Hassan; V Courtney Broaddus; Shannon Wilson; David J Liewehr; Jingli Zhang
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.